

Medical Full Length Article

The Role of the Consciousness Energy Healing Treated Novel Test Formulation on Different Vital Organ Functional Biomarkers

Su-Mei Chen Liu¹, Mahendra Kumar Trivedi¹, Alice Branton¹, Dahryn Trivedi¹, Gopal Nayak¹, Sambhu Charan Mondal² and Snehasis Jana^{2*}

¹Trivedi Global, Inc., Henderson, Nevada, USA

²Trivedi Science Research Laboratory Pvt. Ltd., Thane-West, Maharashtra, India

*Corresponding author's Email: publication@trivedieffect.com (S. Jana)

Accepted 12th August, 2019.

The study objective was to investigate the potential of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs, and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Su-Mei Chen Liu, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of Biofield Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 53.5% (at 0.1 µg/mL), 127.9% (at 10 µg/mL), and 53.3% (at 25 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI group showed 144% and 87.9% restoration of cell viability at 1 and 10 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 195%, 242.5%, and 117.5% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.2% (at 10 µg/mL) in the BT-Med + BT-TI; while 87.6%, 90.5%, and 90.3% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 249.5% and 167.4% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 94.5% (at 0.1 µg/mL) and 77.7% (at 25 µg/mL) in the BT-Med + BT-TI groups, respectively; while 58.4% (at 10 µg/mL) in the BT-Med + BT-TI group compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 70.3% and 106% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively 1 µg/mL compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 95.9% in the UT-Med + BT-TI group at 0.1 µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 58.4% and 135.9% in the BT-Med + BT-TI group at 10 and 25 µg/mL, respectively; while 72.8% (at 25 µg/mL) in the BT-Med + UT-TI group as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 373.2% (at 1 µg/mL) and 263.1% (at 10 µg/mL) in the BT-Med + UT-TI group; while 318.4% (at 1 µg/mL) and 224.4% (at 10 µg/mL) in the BT-Med + BT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect[®]) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect[®] can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, hemochromatosis, cirrhosis, liver cancer, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Keywords: Biofield Energy Treatment, The Trivedi Effect[®], Bone health, Cardiac health, Liver health, Lungs health, VDR receptor, Brain health

1. INTRODUCTION

Bones, heart, liver, lungs, and brain disorders are the major concern of human overall health across the globe. The World Health Organization (WHO) estimates, in 2016, ~17.5 million people die due to cardiovascular (heart) disorders, ~3.5 million people die due to lungs disorders, ~1.3 million people die due to liver disorders around the globe each year (Global Burden of Disease Collaborative Network, 2017). Moreover, ~1.2 million people most frequently diagnosed adult-onset brain disorders in each year in the USA. (Pal 2018). Three main criteria to keep a healthy heart include the opening blood vessels, strengthening the heart muscle, and controlling free radical damage by antioxidants [Rakesh and Arunporn, 2017]. The release of liver mitochondrial enzymes is considered strong evidence for hepatic (liver) necrosis, which is associated with an increased production of reactive oxygen species (ROS) that leads to hepatic lipid peroxidation (Contreras-Zentella and Hernández-Muñoz, 2016; Schmidt and Schmidt 1970; Frederiks et al. 1984). Oxidative stress in the respiratory system increases the production of mediators of pulmonary inflammation and initiate or promote mechanisms of carcinogenesis (Boots 2003). The lung is one of the major organs, which is highly exposed by various oxidants *i.e.*, endogenous and exogenous oxidants (cigarette smoke, mineral dust, ozone, and radiation). These oxidants produce free radicals, while reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced by phagocytes as well as by alveolar, polymorphonuclear, bronchial and different endothelial cells (Romieu 2005). However, the role of oxidative stress in the pathogenesis of lung diseases has been widely reported such as asthma, chronic obstructive pulmonary disease (COPD), lung malignancies and parenchymal lung diseases like idiopathic pulmonary fibrosis and lung granulomatous diseases (Kelly 2005). Serotonin (5-hydroxytryptamine, 5-HT) is among the brain's neuromodulators responsible for behavior and understanding (Fischer and Ullsperger, 2017). Apart from medicines, non-pharmacologic methods that can increase serotonin by increasing recognition and happiness and well-being. These factors can protect against mental and physical disorders (Anonymous 2006). There is currently no universally accepted test formulation, which improve the organ health biomarkers. With this respect, the novel test formulation was designed on the basis of best scientific literature, which is the combination of herbal products *viz.* *Panax ginseng* extract and beta carotene, minerals *viz.* calcium chloride, magnesium gluconate, zinc chloride, sodium selenate, ferrous

sulfate, and vitamins *viz.* vitamin B₁₂, vitamin D₃, ascorbic acid, and vitamin B₆. This formulation is designed for overall functioning of the organs that can results in improved overall health conditions against many pathological conditions such as lung disorder, liver disorder, breast cancer, liver cancer, aging, muscle damage, and overall health. Minerals and vitamins present in the test formulation provide significant functional support to all the vital organs (Ryan-Harshman and Aldoori, 2005; Rayman 2000; Beard and Connor, 2003). In addition, *Panax ginseng* is one of the best reported medicinal plants that improve mental, physical abilities, cognitive health, and is potent immunomodulator (Coleman et al. 2003; Das et al. 2011).

Various study data suggested the effect of Energy Therapy in cancer patients through therapeutic touch (Lutgendorf et al. 2010), massage therapy (Ironson et al. 1996), etc. Complementary and Alternative Medicine (CAM) therapies are preferred model of treatment, among which Biofield Therapy (or Healing Modalities) is one approach to enhance emotional, mental, physical, and human wellness. The National Center of Complementary and Integrative Health (NCCIH) has recognized and allowed Biofield Energy Healing as a CAM approach in addition to other therapies and medicines such as natural products, chiropractic/osteopathic manipulation, Qi Gong, deep breathing, Tai Chi, yoga, meditation, massage, special diets, healing touch, relaxation techniques, traditional Chinese herbs and medicines, naturopathy, movement therapy, homeopathy, progressive relaxation, guided imagery, pilates, acupuncture, acupressure, Reiki, rolfing structural integration, hypnotherapy, Ayurvedic medicine, mindfulness, essential oils, aromatherapy, and cranial sacral therapy. The Human Biofield Energy has subtle energy that has the capacity to work in an effective manner (Jain et al. 2015). CAM therapies have been practiced worldwide with reported clinical benefits in different health disease profiles (Rubik 2002). This energy can be harnessed and transmitted by the practitioners into living and non-living things *via* the process of Biofield Energy Healing. The Biofield Energy Treatment, the Trivedi Effect[®], has been reported to have a significant impact in the field of cancer research (^{a,b}Trivedi et al. 2015), materials science (Trivedi et al. 2008; ^cTrivedi et al. 2015), microbiology (^{d,e}Trivedi et al. 2015), agriculture (^{f,g}Trivedi et al. 2015), nutraceuticals (Trivedi et al. 2017; Parulkar et al. 2018), and biotechnology (^hTrivedi et al. 2015; Nayak and Altekar, 2015). Further, the Trivedi Effect[®] also significantly improved

bioavailability of various low bioavailable compounds (a,b,c) Branton and Jana, 2017) an improved overall skin health (Parulkar et al. 2017; Singh et al. 2017), bone health (Anagnos et al. 2018; Lee et al. 2018; Stutheit et al. 2018), human health and wellness. Based on the excellent outcomes of the Biofield Energy Therapy in wide spectrum of areas, the authors intend to see the impact of the Biofield Energy Healing Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain specific biomarkers in different cell-lines.

2. MATERIALS AND METHODS

2.1. Chemicals and reagents

Zinc chloride, magnesium gluconate, β -carotene, and calcitriol were purchased from TCI chemicals, Japan. Ferrous sulfate, vitamin B₆, vitamin D₃, vitamin B₁₂, calcium chloride, naringenin, trimetazidine (TMZ), 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT), and ethylenediaminetetraacetic acid (EDTA) were obtained from Sigma Chemical Co. (St. Louis, MO). Sodium selenate and ascorbic acid were obtained from Alfa Aesar, India. *Panax ginseng* extract obtained from panacea Phytoextracts, India. Reverse Transcription Kit, RNeasy Mini Kit, and Syber Green PCR kits were procured from Quagen, India. Silymarin and curcumin were obtained from Sanat Chemicals, India and quercetin obtained from Clearsynth, India. All the other chemicals used in this experiment were analytical grade procured from India.

2.2. Biofield energy healing strategy

The test formulation was the combination of eleven ingredients viz. calcium chloride, *Panax ginseng* extract, vitamin B₁₂, β -carotene, vitamin D₃, zinc chloride, magnesium gluconate, sodium selenate, ferrous sulfate, ascorbic acid, and vitamin B₆. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Su-Mei Chen Liu, under laboratory conditions for ~3 minutes through healer's unique Biofield Energy Transmission process and was labeled as the Biofield Energy Treated (BT) test formulation/media. Further, the untreated group was treated with a "sham" healer for comparison purposes.

The "sham" healer did not have any knowledge about the Biofield Energy Healing Treatment. The Biofield Energy Healer was located in the USA, however the test items were located in the research laboratory of Dabur Research Foundation, New Delhi, India. Biofield Energy Healer in this experiment did not visit the laboratory, nor had any contact with the test samples. After that, the Biofield Energy Treated and untreated test items were kept in similar sealed conditions and used for the study as per the study plan.

2.3. Assessment of cell viability using MTT assay

Cells were counted using hemocytometer and plated in 96-well plates at the specific density described in Table 1. The cells were then incubated overnight under growth conditions to allow cell recovery and exponential growth. Following overnight incubation, cells were treated with different concentrations of test formulations (BT/UT). Following respective treatments, cells were incubated in a CO₂ incubator at 37°C, 5% CO₂, and 95% humidity and incubated for time period mentioned in Table 1. After incubation, the plates were taken out and 20 μ L of 5 mg/mL of MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide solution was added to all the wells followed by additional incubation for 3 hours at 37°C. The supernatant was aspirated and 150 μ L of DMSO was added to each well to dissolve formazan crystals. The absorbance of each well was read at 540 nm using Synergy HT microplate reader. The percentage cytotoxicity at each tested concentration of TI was calculated using Equation 1:

$$\% \text{ Cytotoxicity} = [(R-X)/R] * 100 \dots \dots \dots (1)$$

Where, X = Absorbance of treated cells; R = Absorbance of untreated cells

The concentrations exhibiting percentage cytotoxicity < 30% were considered as non-cytotoxic (Alía et al. 2005).

Table 1: Information related to six cell lines with their plating density and time-point.

S. No.	Cell Line	Plating	Time Point
1	MG-63 (Bone)	3x10 ⁴ cells/ well, 96-well plate	5 days
2	Ishikawa (Uterus)	3x10 ⁴ cells/ well, 96-well plate	5 days
3	A549 (Lung)	10x10 ⁴ cells/ well, 96-well plate	24 hours
4	HepG2 (Liver)	1x10 ⁴ cells/ well, 96-well plate	24 hours
5	Human Cardiac fibroblasts (Heart)	1x10 ⁴ cells/ well, 96-well plate	24 hours
6	SH-SY5Y (Neuronal cell)	10x10 ⁴ cells/ well, 96-well plate	24 hours

2.4. Evaluation of the cytoprotective effect of the formulation

Cells (human cardiac fibroblasts-HCF; human hepatoma cells-HepG2; and adenocarcinomic human alveolar basal epithelial cells-A549) were counted and plated in suitable medium followed by overnight incubation. The cells were then treated with the test items/positive control at the non-cytotoxic concentrations for 24 hours. After 24 hours, oxidative stress was given to the cells using 10mM t-BHP for 3.5 hours. The untreated cells served as a control that did not receive any treatment and was maintained in cell growth medium only. Cells treated with 10mM of t-BHP alone served as negative control. After 3.5 hours of incubation with t-BHP the above plates were taken out and cell viability was determined by MTT assay. The percentage protection corresponding to each treatment was calculated using Equation 2:

$$\% \text{ Protection} = \frac{[(\text{Absorbance}_{\text{sample}} - \text{Absorbance}_{\text{t-BHP}})] * 100}{[\text{Absorbance}_{\text{untreated}} - \text{Absorbance}_{\text{t-BHP}}]} \dots \dots \dots (2)$$

2.5. Assessment of alkaline phosphatase (ALP) activity

The cells (human bone osteosarcoma cells-MG-63 and human endometrial adenocarcinoma cells-Ishikawa) were counted using a hemocytometer and

plated in 24-well plates at the density corresponding to 1 X 10⁴ cells/well in phenol-free DMEM supplemented with 10% CD-FBS. Following the respective treatments, the cells in the above plate were incubated for 48 hours in CO₂ incubator at 37°C, 5% CO₂, and 95% humidity. After 48 hours of incubation, the plates were taken out and processed for the measurement of ALP enzyme activity. The cells were washed with 1 X PBS and lysed by freeze-thaw method *i.e.*, incubation at -80°C for 20 minutes followed by incubation at 37°C for 10 minutes. To the lysed cells, 50 µL of substrate solution *i.e.*, 5 mM of p-nitrophenyl phosphate (pNPP) in 1M diethanolamine and 0.24 mM magnesium chloride (MgCl₂) solution (pH 10.4) was added to all the wells followed by incubation for 1 hour at 37°C. The absorbance of the above solution was read at 405 nm using Synergy HT microplate reader (Biotek, USA). The absorbance values obtained were normalized with substrate blank (pNPP solution alone) absorbance values. The percentage increase in ALP enzyme activity with respect to the untreated cells (baseline group) was calculated using Equation 3:

$$\% \text{ Increase in ALP} = \frac{(X-R)}{R} * 100 \dots \dots \dots (3)$$

Where, X = Absorbance of cells corresponding to positive control and test groups

R = Absorbance of cells corresponding to baseline group (untreated cells)

2.6. Estimation of lactate dehydrogenase (LDH) in human cardiac fibroblasts (HCF)

The human cardiac fibroblasts (HCF) Cells were counted and plated at the density of 0.25×10^6 cells/ well in 24-well plates in cardiac fibroblast specific medium followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations for 24 hours. After 24 hours, oxidative stress was given to the cells using 10mM *t*-BHP for 3.5 hours. The untreated cells were served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 10mM of *t*-BHP alone served as the negative control. After 3.5 hours of incubation with *t*-BHP the above plates were taken out and LDH activity was determined using LDH activity kit as per manufacturer's instructions. The percent increase in LDH activity was calculated using Equation 4.

$$\% \text{ Increase} = \frac{[(\text{LDH activity}_{\text{sample}} - \text{LDH activity}_{\text{t-BHP}})] * 100}{[\text{LDH activity}_{\text{untreated}} - \text{LDH activity}_{\text{t-BHP}}]} \dots \dots \dots (4)$$

2.7. Estimation of ALT in liver cells (HepG2)

The human hepatoma cells (HepG2) were counted and plated at the density of 5×10^4 cells/well in 48-well plates in DMEM media followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations for 24 hours. After 24 hours, oxidative stress was given to the cells using 400 μ M *t*-BHP for 3.5 hours. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 400 μ M of *t*-BHP alone served as negative control. After 3.5 hours of incubation with *t*-BHP the above plates were taken out and ALT activity was determined using ALT activity kit as per manufacturer's instructions. The percent increase in ALT activity was calculated using Equation 5.

$$\% \text{ Increase} = \frac{[(\text{ALT activity}_{\text{sample}} - \text{ALT activity}_{\text{t-BHP}})] * 100}{[\text{ALT activity}_{\text{untreated}} - \text{ALT activity}_{\text{t-BHP}}]} \dots \dots \dots (5)$$

2.8. Estimation of superoxide dismutase (SOD) in lung (A549) cells

The adenocarcinomic human alveolar basal epithelial cells (A549) were counted and plated at the density of 1×10^4 cells/well in 24-well plates in DMEM

followed by overnight incubation. The cells were then treated with the test formulation/ positive control at the non-cytotoxic concentrations along with 100 μ M *t*-BHP to induce oxidative stress. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 100 μ M of *t*-BHP alone served as negative control. After 24 hours of incubation with *t*-BHP the above plates were taken out and SOD activity was determined using SOD activity kit as per manufacturer's instructions. The percent increase in SOD activity was calculated using Equation 6:

$$\% \text{ Increase in SOD activity} = \frac{(X-R)}{R} * 100 \dots \dots \dots (6)$$

Where, X = SOD activity corresponding to Test Item or Positive Control
R = SOD activity corresponding to Control group.

2.9. Estimation of serotonin in neuronal cells (SH-SY5Y)

The human neuroblastoma (SH-SY5Y) cells were counted and plated at the density of 10×10^4 cells/well in 96-well plates followed by overnight incubation. The cells were then treated with the test items/positive control at the non-cytotoxic concentrations. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. The treated cells were incubated for 24 hours. Serotonin release was determined by ELISA as per manufacturer's protocol. The percent increase in serotonin levels was calculated using Equation 7.

$$\frac{(X-R)}{R} * 100 \dots \dots \dots (7)$$

Where, X = Serotonin levels corresponding to test item or positive control
R = Serotonin levels corresponding to control group.

2.10. Effect of test formulation on vitamin D receptor (VDR) in bone (MG-63) cells

The human bone osteosarcoma (MG-63) cells were counted using the hemocytometer were plated at a density of 2×10^5 cells/well in 6-well plates followed by overnight incubation. The cells were then sera starved for 24 hours and treated with the test formulation/positive control at the non-cytotoxic concentrations. The untreated cells that served as control that did not receive any treatment and were maintained in cell growth medium only. The treated cells were incubated for 24 hours and VDR expression was determined by Q-PCR using VDR specific primers.

Cells were harvested by scrapping and washed with PBS. Cell pellets obtained were analyzed for VDR gene expression using human VDR specific primers: Forward: 5'-GCTGACCTGGTCAGTTACAGCA-3', Reverse: 5'-CACGTCAGTACGCGGTACTT-3'. VDR gene expression was normalized using House-keeping (HK) reference. Relative quantification (RQ) of VDR gene in Biofield Energy Treated cells was calculated with respect to the untreated cells using Equation 8:

$$RQ = 2^{-N} \dots \dots \dots (8)$$

Where N is the relative Threshold Cycle (CT) value of treated sample with respect to the untreated sample.

2.11. Statistical analysis

All the values were represented as Mean \pm SD (standard deviation) of three independent experiments. The statistical analysis was performed using Sigma Plot statistical software (v11.0). For two groups comparison student's *t*-test was used. For multiple group comparison, one-way analysis of variance (ANOVA) was used followed by post-hoc analysis by Dunnett's test. Statistically significant values were set at the level of $p \leq 0.05$.

3. RESULTS AND DISCUSSION

3.1. Cell viability using MTT assay

Determination of non-cytotoxic concentration of the formulation and positive controls by MTT cell viability assay was used in terms of percent viable cells in six (6) different cell-lines viz. MG-63, Ishikawa, A549, HepG2, HCF, and SH-SY5Y. Based on the percent cell viability data, it was observed that the formulation and positive controls were safe and non-toxic at the tested concentrations in six different cell lines and selected for other parameters analysis.

3.2. Evaluation of cytoprotective effect of the test formulation

The cytoprotective activity of the novel proprietary test formulation on vital organs like liver, heart, and lungs was examined in *in vitro* cell-based assay under the stimulation of *tert*-butyl hydroperoxide (*t*-BHP) induced oxidative stress. *t*-BHP has been routinely used for the induction of oxidative stress in various cells (Vargas-Mendoza et al. 2014). The

cytoprotective activity of the Biofield Energy Treated test formulation on the restoration of cell viability was determined against *t*-BHP induced cell damage and the result is shown in Figure 1. Trimetazidine (TMZ) was used as positive control in human cardiac fibroblasts cells (HCF) and showed, restoration of cell viability by 56.61%, 94.09%, and 102.29% at 5, 10, and 25 $\mu\text{g/mL}$, respectively compared to the *t*-BHP induced group. Besides, the test formulation showed 53.5% restoration of cell viability at 0.1 $\mu\text{g/mL}$ in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group. Moreover, at 1 $\mu\text{g/mL}$ the UT-Med + BT-TI and BT-Med + UT-TI groups showed 34.1% and 12.9% restoration of cell viability, respectively than UT-Med + UT-TI group. Additionally, the test formulation showed 23.7% and 127.9% restoration of cell viability at 10 $\mu\text{g/mL}$ in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group. Further, at 25 $\mu\text{g/mL}$ the test formulation showed 52.9% and 53.3% restoration of cell viability, respectively in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively than UT-Med + UT-TI group (Figure 1). Silymarin was used as positive control in human hepatoma cells (HepG2) resulted, restoration of cell viability by 38.79%, 73.92%, and 81.74% at 5, 10 and 25 $\mu\text{g/mL}$, respectively compared to the *t*-BHP induced group. Besides, the test formulation showed 144%, 87.9%, and 35.7% restoration of cell viability at 1, 10, and 25 $\mu\text{g/mL}$ in the UT-Med + BT-TI group as compared to the UT-Med + UT-TI group. Moreover, at 63 $\mu\text{g/mL}$ the UT-Med + BT-TI and BT-Med + UT-TI groups showed 43.1% and 19.4% restoration of cell viability than UT-Med + UT-TI group (Figure 1). Quercetin was used as positive control in adenocarcinomic human alveolar basal epithelial cells (A549) resulted, restoration of cell viability by 31.2%, 41.93%, and 55.74% at 5, 10 and 25 $\mu\text{g/mL}$, respectively compared to the *t*-BHP induced group. Besides, the test formulation showed 195%, 242.5%, and 117.5% restoration of cell viability at 0.1 $\mu\text{g/mL}$ in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the UT-Med + UT-TI group. Moreover, at 1 $\mu\text{g/mL}$ the UT-Med + BT-TI and BT-Med + BT-TI groups showed 174.7% and 98.7% restoration of cell viability, respectively than UT-Med + UT-TI group. Additionally, the test formulation showed 37.7% restoration of cell viability at 10 $\mu\text{g/mL}$ in the UT-Med + BT-TI group compared to the UT-Med + UT-TI group. Further, the test formulation showed 39.7%, 38.4%, and 15.8% restoration of cell viability at 25 $\mu\text{g/mL}$ in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups,

respectively compared to the UT-Med + UT-TI group. Besides, at 63 $\mu\text{g/mL}$ the test formulation exhibited 19.7% restoration of cell viability in the UT-Med + BT-TI group as compared to the UT-Med + UT-TI group (Figure 1). The study results suggest that Biofield Treatment has significantly protects *t*-BHP induced cardiotoxicity, hepatotoxicity, and lung cell toxicity

which could be due to The Trivedi Effect[®]-Biofield Energy Healing. Therefore, Biofield Energy Healing Treatment could be used for the management of cardiovascular, liver, and various lung disorders.




Figure 1: Assessment of cytoprotective effect of the test formulation in human cardiac fibroblasts cells (HCF), human hepatoma cells (HepG2), and adenocarcinomic human alveolar basal epithelial cells (A549) against *tert*-butyl hydroperoxide (*t*-BHP) induced damage. TMZ: Trimetazidine (μM), silymarin ($\mu\text{g/mL}$), and quercetin (μM) were used as positive control in HCF, HepG2, and A549 cells, respectively. UT: Untreated; Med: Medium; BT: Biofield Treated; TI: Test item.

3.3. Assessment of Alkaline Phosphatase (ALP) Activity

The effect of the test formulation on bone-specific alkaline phosphatase level is shown in Figure 2. The positive control, calcitriol showed 24.82%, 33.7%, and 62.95% increased the level of ALP at 0.1, 1, and 10 nM, respectively in MG-63 cells. Moreover, the experimental groups showed 43.2% and 46% increased the level of ALP in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively with respect to the UT-Med + UT-TI group at 1 $\mu\text{g/mL}$. At 10 $\mu\text{g/mL}$, the percent ALP was significantly increased by 66.9%, 86.5%, and 94.2% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the UT-Med + UT-TI group. Further, the

percent ALP was significantly increased by 87.6%, 90.5%, and 90.3% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 $\mu\text{g/mL}$ compared to the UT-Med + UT-TI group (Figure 2). Besides, the positive control, naringenin showed 21.5%, 39.43%, and 113.64% increased the level of ALP at 0.1, 1, and 10 nM, respectively in Ishikawa cells. ALP percent was significantly increased by 249.5%, 63.2%, and 167.4% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively compared to the UT-Med + UT-TI group at 1 $\mu\text{g/mL}$. Moreover, the experimental groups showed 45.8% and 16.9% increased the level of ALP in the BT-Med + UT-

TI and BT-Med + BT-TI groups, respectively with respect to the UT-Med + UT-TI group at 10 µg/mL. At 50 µg/mL, the percent ALP was significantly increased by 25.6%, 17.8%, and 26.2% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the UT-Med + UT-TI group (Figure 2). Several studies indicated that lower level of serum alkaline phosphatase (ALP) can improve the bone mineral density in patients related to the bone - related disorders (Park et al. 2010). The level of ALP enzyme activity become high in Most of the patients with bone metastatic carcinoma and osteogenic sarcoma (Ross et al. 1998). Thus, for the detection of

bone specific biochemical marker in serum can be clinically useful in evaluating the progress of the bone healing process (Emami et al. 1999; Komnenou et al. 2005). In this experiment, the level of ALP was revealed that the Biofield Energy Healing Treated test formulation significantly increased the level of ALP expression, which might be very helpful to the patients suffering from various bone-related disorders.




Figure 2: The effect of the test formulation on alkaline phosphatase (ALP) in A. Human bone osteosarcoma cells (MG-63) and B. Human endometrial adenocarcinoma cells (Ishikawa). Calcitriol and naringenin were used as positive control in Mg-63 and Ishikawa cells, respectively. UT: Untreated; Med: Medium; BT: Biofield Treated; TI: Test item.

3.4. Estimation of lactate dehydrogenase (LDH) activity in human cardiac fibroblasts (HCF)

The effect of test items on the percent protection of HCF cells in terms of decreased level of lactate dehydrogenase (LDH) activity is shown in Figure 3. The positive control, trimetazidine (TMZ) exhibited 30.14%, 69.42%, and 80.06% protection of HCF cells (decreased of LDH activity) compared to the t-BHP group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 94.5% and 17.1% in the BT-Med + UT-TI and BT-

Med + BT-TI groups, respectively at 0.1 µg/mL as compared to the UT-Med + UT-TI group. Moreover, at 1 µg/mL, the percent protection of HCF cells (decreased of LDH activity) was significantly increased by 30.9% and 48.8% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group. Further, percent protection of HCF cells (decreased of LDH activity) was also significantly increased by 13.5%, 46.4%, and 58.4% in

the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 $\mu\text{g/mL}$ as compared to the UT-Med + UT-TI group. Further, percent protection of HCF cells (decreased of LDH activity) was also significantly increased by 37.3%, 77.7%, and 51.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 25 $\mu\text{g/mL}$ as compared to the UT-Med + UT-TI group (Figure 3). The lactate dehydrogenase (LDH) enzyme is mainly present in the heart and skeletal muscle, and responsible for anaerobic respiration of cells (Burgner and Ray, 1984). Various heavy metals contamination can increased the level of LDH and simultaneously more prone to CVDs

(Liao et al. 2012). The study results found that there was a significant reduction of LDH level after Biofield Energy Treatment and protect heart cells, which might be helpful to resist against various pathological conditions like tissue injury, necrosis, hemolysis or malignancies, hypoxia, etc. It also indicating that the heart cells acted normally under stress and anaerobic condition and improved overall heart function.




Figure 3: The effect of the test formulation on the percent protection of HCF cells in terms of decreased lactate dehydrogenase (LDH) activity against tert-butyl hydroperoxide (t-BHP) induced damage. TMZ: Trimetazidine; UT: Untreated; Med: Medium; BT: Biofield Treated; TI: Test item.

3.5. Estimation of alanine amino transferase (ALT) activity in HepG2 cells

The effect of the test formulation on protection of HepG2 cells in terms of decrease alanine amino transferase (ALT) activity is shown in Figure 4. The positive control, silymarin exhibited 6.52%, 74.51%, and 106.27% protection of HepG2 cells (decreased of ALT activity). The protection of HepG2 cells (decreased of ALT activity) was significantly increased by 70.3%, 37.2% and 106% at 1 $\mu\text{g/mL}$ in the UT-Med

+ BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group. Moreover, at 10 $\mu\text{g/mL}$ percent protection of HepG2 cells (decreased of ALT activity) was increased by 20.8% in the BT-Med + UT-TI group as compared to the UT-Med + UT-TI group. Further, protection of HepG2 cells (decreased of ALT activity) was also significantly increased by 15% and 32.5% in the UT-

Med + BT-TI and BT-Med + BT-TI groups, respectively at 25 µg/mL as compared to the UT-Med + UT-TI group (Figure 4). Abnormal levels of liver enzyme like ALT causes liver damage or change in bile flow capacity by either accompanying biochemical picture in a patient with symptoms or signs (Giannini et al. 2005). This enzyme can catalyze the reversible transformation of α-ketoacids into amino acids and play as a predictor of mortality independent of liver disease (Mathiesen et al. 1999; Price and Alberti, 1981). Here, the Biofield

Energy Treatment significantly protect liver hepatocytes in terms of reducing the level of transaminases enzyme, ALT compared to the t-BHP inducing group, which might be due to Consciousness Energy Healing Treatment to the test formulation




Figure 4: Effect of the test formulation on the percent protection of human liver cancer (HepG2) cells in terms of decreased alanine amino transaminase (ALT) activity under the stimulation of tert-butyl hydroperoxide (t-BHP). UT: Untreated; Med: Medium; BT: Biofield Treated; TI: Test item.

3.6. Estimation of superoxide dismutase (SOD) activity in adenocarcinomic human alveolar basal epithelial cells (A549)

The effect of the test formulation on the protection of lungs cells (A549) in terms of increased super oxide dismutase (SOD) activity is shown in Figure 5. The positive control, showed 80.67%, 97.01%, and 109.56% protection of A549 (lungs) cells (increased of SOD activity) compared to the t-BHP group. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 95.9% and 10.9% at 0.1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the UT-Med + UT-TI group. Moreover, at 25 µg/mL,

the percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 13.7%, 13.7%, and 10.9% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group (Figure 5). Numerous studies reported that body defense antioxidant enzyme super oxide dismutase (SOD) plays an important role against various respiratory disorders. Increased oxidative stress leads to the pathogenesis of various obstructive lung disorders such as asthma, chronic obstructive pulmonary

disease (COPD), lung malignancies, etc. Several genetic studies also have identified the link between extracellular SOD polymorphisms and risk for developing chronic obstructive pulmonary disorders (COPD) and asthma (Oberley-Deegan et al. 2009; Smith et al. 1997). Altogether, data observed that a significant increased SOD level after Biofield Energy

Treatment in A549 cells, which might be helpful to resist against various pathological conditions like oxidative stress and related adverse effect. It also indicating that the lung cells acted normally and improved overall respiratory activities.




Figure 5: Effect of the test formulation on the percent protection of lungs cells (A549) in terms of increased SOD activity under the stimulation of tert-butyl hydroperoxide (t-BHP). UT: Untreated; Med: Medium; BT: Biofield Treated; TI: Test item.

3.7. Effect of test formulation on serotonin in human neuroblastoma (SH-SY5Y) cells

The effect of test formulation on serotonin levels is shown in Figure 6. The positive control, showed 98.2%, 123.53%, and 156.76% increased the level of serotonin. The level of serotonin was significantly increased by 23%, 56.2%, and 37.2% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively at 1 μg/mL compared to the UT-Med + UT-TI group. Moreover, at 10 μg/mL, 5-HT level was significantly increased by 39.6%, 72.8%, and 58.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group. Further, the serotonin level was significantly increased by 37.3% and 135.9% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 25 μg/mL as compared to the UT-Med + UT-TI

group (Figure 6). Serotonin (5-HT) is a neurotransmitter produced in neurons, gut, and heart cell mainly and responsible for stress, anxiety, aggressive behavior, and for the regulation of blood pressure (Dorszewska et al. 2013). Dysfunction of 5-HT has been directly correlated with psychiatric and neurological disorders (Deneris and Gaspar, et al. 2018). Moreover, 5-HT act as a neuromodulator in the central nervous system (Daubert and Condron, 2010). Thus, this experimental data suggested that Biofield Energy Healing Treated novel formulation significantly improved the serotonin level, which would be highly useful against various neurodegenerative diseases and other age-related disorders and improved the normal functioning of the brain tissues.




Figure 6: Effect of the test formulation on percent increase in 5-hydroxy tryptamine (5-HT) or serotonin in human neuroblastoma cells (SH-SY5Y). UT: Untreated; Med: Medium; BT: Biofield Treated; TI: Test item

3.8. Effect of test formulation on vitamin D receptors (VDRs)

Human bone osteosarcoma cells (MG-63) were treated with the test formulation and the effect on vitamin D receptor (VDR) expression was determined using quantitative-polymerase chain reaction (Q-PCR) amplification. VDR-relative threshold cycle (VDR-CT) values were obtained from PCR amplification. Relative quantification (RQ) of VDR was calculated from the VDR-CT and house-keeping (HK)-CT values for MG-63 cells treated with test formulation and positive control is shown in Figure 7. The positive control (calcitriol) showed 32.87%, 61.33%, and 107.05% increase of RQ of VDR at 0.1, 1, and 10 nM, respectively. Moreover, RQ-VDR was significantly increased by 157.6% and 113.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1 μg/mL compared to the UT-Med + UT-TI group. Additionally, at 1 μg/mL the VDR level was significantly increased by 204.3%, 373.2%, and 318.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the UT-Med + UT-TI group. Further, VDR level was also significantly increased by 201.3%, 263.1%, and 224.4% in the UT-

Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 μg/mL compared to the UT-Med + UT-TI group. Continuously literature supported that deficiencies in vitamin D receptor (VDR) activation leads to cardiovascular disorders, hyperparathyroidism, and even chronic kidney diseases (Cozzolino and Malindretos, 2010). Vitamin D and vitamin D receptor (VDR) are also plays a vital roles in oral cancer by interacting with the vitamin D receptor (VDR), both in healthy and diseased individuals (Fathi et al. 2019). The active metabolite of vitamin D can bind to (VDR) and activates its specific nuclear receptor that can prevents the release of calcium from its storage in bone to serum by stimulating intestinal calcium absorption and renal reabsorption (Yamamoto et al. 2013). Overall, the Consciousness Energy Treated test formulation has excellently increased the expression of VDRs, which might be helpful to bind more active vitamin D₃ metabolites and that ultimately can improve the more physiological functions of vitamin D and simultaneously improved bone cell growth and development.




Figure 7: Effect of the test formulation on percent increase in relative quantification (RQ) of vitamin D receptors (VDRs) gene in human bone osteosarcoma cells (MG-63). UT: Untreated; Med: Medium; BT: Biofield Treated; TI: Test item

4. CONCLUSIONS

The study findings showed that the tested novel test formulation was safe and non-toxic based on MTT cell viability assay in six tested cells. The treatment group like BT-Med + BT-TI showed 53.5%, 127.9%, and 53.3% restoration of cell viability at 0.1, 10, and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI group showed 144% and 87.9% restoration of cell viability at 1 and 10 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Additionally, 195%, 242.5%, and 117.5% restoration of cell viability at 0.1 µg/mL in adenocarcinomic human alveolar basal epithelial cells (A549) compared to the untreated group. Alkaline phosphatase (ALP) activity was significantly increased by 94.2% in the BT-Med + BT TI group at 10 µg/mL; while 87.6%, 90.5%, and 90.3% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63). Moreover, ALP activity was significantly increased by 249.5% and 167.4% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL than untreated group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 94.5% and 77.7% at 1 and 25 µg/mL, respectively in the BT-Med +

BT-TI group compared to the untreated group in HCF cells. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 106% in the BT-Med + BT-TI group 1 µg/mL compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 95.9% in the UT-Med + BT-TI group at 0.1 µg/mL compared to the untreated group in A549 cells. The serotonin level was significantly increased by 135.9% at 25 µg/mL in the BT-Med + UT-TI group as compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 373.2% and 318.4% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to the untreated group in MG-63 cells. In conclusion, The Biofield Energy Treatment significantly improved heart, liver, bones, neuronal, and lungs related functional enzymes and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte, and nerve cells from oxidative damage induced by *tert*-butyl hydroperoxide (*t*-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders

(peripheral artery disease, high blood pressure, congenital heart disease, stroke, congestive heart failure, rheumatic heart disease, carditis, valvular heart disease, thromboembolic disease, and venous thrombosis, etc.), hepatic disorders (cirrhosis, Wilson disease, liver cancer, hemochromatosis), and lungs disorders (Asthma, Emphysema, Chronic bronchitis, Pneumonia, Cystic fibrosis). Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (*i.e.*, liver, kidney, and heart transplants), aging, hormonal imbalance and various inflammatory and immune-related disease conditions like Alzheimer's Disease (AD), Dermatitis, Asthma, Ulcerative Colitis (UC), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Aplastic Anemia, Multiple Sclerosis, Hepatitis, Graves' Disease, Irritable Bowel Syndrome (IBS), Dermatomyositis, Diabetes, Myasthenia Gravis, Atherosclerosis, Parkinson's Disease, Systemic etc. to Lupus Erythematosus (SLE), stress, improve overall health and Quality of Life.

ACKNOWLEDGEMENTS

Authors gratefully acknowledged to Trivedi Global, Inc., Trivedi Science, and Trivedi Master Wellness for their support. In addition, authors are thankful for the support of Dabur Research Foundation for conducting this study.

REFERENCES

- ^aBranton A, Jana S (2017) The influence of energy of consciousness healing treatment on low bioavailable resveratrol in male *Sprague Dawley* rats. *International Journal of Clinical and Developmental Anatomy* 3: 9-15.
- Alía M, Ramos S, Mateos R, Bravo L, Goya L (2005) Response of the antioxidant defense system to *tert*-butyl hydroperoxide and hydrogen peroxide in a human hepatoma cell line (HepG2). *J Biochem Mol Toxicol* 19: 119-128.
- Anagnos D, Trivedi K, Branton A, Trivedi D, Nayak G et al. (2018) Influence of biofield treated vitamin D₃ on proliferation, differentiation, and maturation of bone-related parameters in MG-63 cell-line. *International Journal of Biomedical Engineering and Clinical Science* 4: 6-14.
- Anonymous (2006) A sensible 10-year plan for mental health. *Lancet* 367: 86.
- ^aTrivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) The potential impact of biofield treatment on human brain tumor cells: A time-lapse video microscopy. *J Integr Oncol* 4: 141.
- ^bBranton A, Jana S (2017) The use of novel and unique biofield energy healing treatment for the improvement of poorly bioavailable compound, berberine in male *Sprague Dawley* rats. *American Journal of Clinical and Experimental Medicine* 5: 138-144.
- Beard JL, Connor JR (2003) Iron status and neural functioning. *Ann Rev Nutr* 23: 41-58.
- Boots AW, Haenen GR, Bast A (2003) Oxidant metabolism in chronic obstructive pulmonary disease. *Eur Respir J* 46: 14S-27S.
- ^bTrivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) *In vitro* evaluation of biofield treatment on cancer biomarkers involved in endometrial and prostate cancer cell lines. *J Cancer Sci Ther* 7: 253-257.
- Burgner JW, Ray WJ (1984) On the origin of the lactate dehydrogenase induced rate effect. *Biochemistry* 23: 3636-3648.
- ^cBranton A, Jana S (2017) Effect of The biofield energy healing treatment on the pharmacokinetics of 25-hydroxyvitamin D₃ [25(OH)D₃] in rats after a single oral dose of vitamin D₃. *American Journal of Pharmacology and Phytotherapy* 2: 11-18.
- Coleman CI, Hebert JH, Reddy P (2003) The effects of *Panax ginseng* on quality of life. *J Clin Pharm Ther* 28(1): 5-15.
- Contreras-Zentella ML, Hernández-Muñoz R (2016) Is liver enzyme release really associated with cell necrosis induced by oxidant stress? *Oxid Med Cell Longev* 2016: 3529149.
- Cozzolino M, Malindretos P (2010) The role of vitamin D receptor activation in chronic kidney disease. *Hippokratia* 14(1): 7-9.
- ^cTrivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O (2015) Studies of the atomic and crystalline characteristics of ceramic oxide nano powders after bio field treatment. *Ind Eng Manage* 4: 161.
- Das L, Bhaumik E, Raychaudhuri U, Chakraborty R (2011) Role of nutraceuticals in human health. *J Food Sci Technol* 49(2):173-183.

- Daubert EA, Condrón BG (2010) Serotonin: A regulator of neuronal morphology and circuitry. *Trends Neurosci* 33(9): 424-434.
- Deneris E, Gaspar P (2018) Serotonin neuron development: Shaping molecular and structural identities. *Wiley Interdiscip Rev Dev Biol* 7(1).
- Dorszewska J, Prendecki M, Oczkowska A, Rozycka A, Lianeri M, Kozubski W (2013) Polymorphism of the COMT, MAO, DAT, NET and 5-HTT genes, and biogenic amines in Parkinson's disease. *Current Genomics* 14: 518-533.
- ^dTrivedi MK, Branton A, Trivedi D, Nayak G, Charan S et al. (2015) Phenotyping and 16S rDNA analysis after biofield treatment on *Citrobacter braakii*: A urinary pathogen. *J Clin Med Genom* 3: 129.
- Emami A, Larsson A, Petré-Mallmin M, Larsson S. (1999) Serum bone markers after intramedullary fixed tibial fractures. *Clin Orthop Relat Res* 368: 220-229.
- ^eTrivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) An impact of biofield treatment: Antimycobacterial susceptibility potential using BACTEC 460/MGIT-TB System. *Mycobact Dis* 5: 189.
- Fathi N, Ahmadian E, Shahi S, Roshangar L, Khan H, Kouhsoltani M, Maleki Dizaj S, Sharifi S (2019) Role of vitamin D and vitamin D receptor (VDR) in oral cancer. *Biomed Pharmacother* 109: 391-401.
- Fischer AG, Ullsperger M (2017) An update on the role of serotonin and its interplay with dopamine for reward. *Front Hum Neurosci* 11: 484.
- Frederiks WM, Vogels IM, Fronik GM (1984) Plasma ornithine carbamyl transferase level as an indicator of ischaemic injury of rat liver. *Cell Biochem Funct* 2: 217-220.
- ^fTrivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC et al. (2015) Morphological characterization, quality, yield and DNA fingerprinting of biofield energy treated alphonso mango (*Mangifera indica* L.). *Journal of Food and Nutrition Sciences* 3: 245-250.
- Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: A guide for clinicians. *CMAJ*. 172(3): 367-379.
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2017.
- ^gTrivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC et al. (2015) Evaluation of biochemical marker – Glutathione and DNA fingerprinting of biofield energy treated *Oryza sativa*. *American Journal of BioScience* 3: 243-248.
- ^hTrivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Phenotypic and biotypic characterization of *Klebsiella oxytoca*: An impact of biofield treatment. *J Microb Biochem Technol* 7: 203-206.
- Ironson G, Field T, Scafidi F, Hashimoto M, Kumar M et al. (1996) Massage therapy is associated with enhancement of the immune system's cytotoxic capacity. *Int J Neurosci* 84: 205-217.
- Jain S, Hammerschlag R, Mills P, Cohen L, Krieger R et al. (2015) Clinical studies of biofield therapies: Summary, methodological challenges, and recommendations. *Glob Adv Health Med* 4: 58-66.
- Kelly FJ (2005) Vitamins and respiratory disease: Antioxidant micronutrients in pulmonary health and disease. *Proc Nutr Soc* 64: 510-526.
- Kommenou A, Karayannopoulou M, Polizopoulou ZS, Constantinidis TC, Dessiris A (2005) Correlation of serum alkaline phosphatase activity with the healing process of long bone fractures in dogs. *Vet Clin Pathol* 34: 35-38.
- Lee AC, Trivedi K, Branton A, Trivedi D, Nayak G et al. (2018) The potential benefits of biofield energy treated vitamin D₃ on bone mineralization in human bone osteosarcoma cells (MG-63). *International Journal of Nutrition and Food Sciences* 7: 30-38.
- Liao YT, Chen CJ, Li WF, Hsu LI, Tsai LY, Huang YL, Sun CW, Chen WJ, Wang SL (2012) Elevated lactate dehydrogenase activity and increased cardiovascular mortality in the arsenic-endemic areas of southwestern Taiwan. *Toxicol Appl Pharmacol* 262(3): 232-7.
- Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G et al. (2010) Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. *Brain Behav Immun* 24: 1231-1240.
- Mathiesen U, Franzen L, Fryden A, Foberg U, Bodemar G (1999) The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. *Scand J Gastroenterol* 34: 85-91.
- Nayak G, Altekar N (2015) Effect of biofield treatment on plant growth and adaptation. *J Environ*

- Health Sci 1: 1-9.
- Oberley-Deegan RE, Regan EA, Kinnula VL, Crapo JD (2009) Extracellular superoxide dismutase and risk of COPD. *COPD* 6(4): 307-312.
- Pal S (2018) Incidence and prevalence of major neurologic disorders. *US Pharm* 43(1): 24.
- Park JC, Kovesdy CP, Duong U, Streja E, Rambod M, Nissenson AR, Sprague SM, Kalantar-Zadeh K (2010) Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. *Hemodial Int* 14(2): 182-192.
- Parulkar VR, Trivedi MK, Branton A, Trivedi D, Nayak G et al. (2018) Improved metabolism of vitamin d3 in human osteoblasts cells after biofield energy healing treatment. *American Journal of Laboratory Medicine* 3: 11-19.
- Parulkar VR, Trivedi MK, Branton A, Trivedi D, Nayak G et al. (2017) The use of consciousness energy healing based herbomineral formulation for skin anti-aging strategies. *Journal of Food and Nutrition Sciences* 5: 96-106.
- Price C, Alberti K (1979) Biochemical assessment of liver function. In: Wright R, et al., eds. *Liver and biliary diseases - pathophysiology, diagnosis, management*. London: W. B. Saunders, 1979: 381-416.
- Rakesh S, Arunporn I (2017) Herbal supplements or herbs in heart disease: Herbaceutical formulation, clinical trials, futuristic developments. *J Cardiol Cardiovasc Ther* 3(1): 555603.
- Rayman MP (2000) The importance of selenium to human health. *Lancet* 356: 233-241.
- Romieu I (2005) Nutrition and lung health. *Int J Tuberc Lung Dis* 9: 362-374.
- Ross PD, Knowlton W (1998) Rapid bone loss is associated with increased levels of biochemical markers. *J Bone Miner Res* 13: 297-302.
- Rubik B (2002) The biofield hypothesis: Its biophysical basis and role in medicine. *J Altern Complement Med* 8: 703-717.
- Ryan-Harshman M, Aldoori W (2005) Health benefits of selected minerals. *Can Fam Physician* 51(5): 673-675.
- Schmidt E, Schmidt FW (1970) Aspects of enzyme diagnosis. *Med Welt* 21: 805-816.
- Singh J, Trivedi MK, Branton A, Trivedi D, Nayak G et al. (2017) Consciousness energy healing treatment based herbomineral formulation: A safe and effective approach for skin health. *American Journal of Pharmacology and Phytotherapy* 2: 1-10.
- Smith LJ, Shamsuddin M, Sporn PH, Denenberg M, Anderson J Reduced superoxide dismutase in lung cells of patients with asthma. (1997) *Free Radic Biol Med* 22(7): 1301-7.
- Stutheit ME, Trivedi K, Branton A, Trivedi D, Nayak G et al. (2018) Biofield energy treated vitamin D₃: Therapeutic implication on bone health using osteoblasts cells. *American Journal of Life Sciences* 6: 13-21.
- Trivedi MK, Branton A, Trivedi D, Nayak G, Plikerd WD et al. (2017) A Systematic study of the biofield energy healing treatment on physicochemical, thermal, structural, and behavioral properties of magnesium gluconate. *International Journal of Bioorganic Chemistry* 2: 135-145.
- Trivedi MK, Tallapragada RM (2008) A transcendental to changing metal powder characteristics. *Met Powder Rep* 63: 22-28, 31.
- Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, Esquivel-Soto J, Esquivel-Chirino C et al. (2014) Hepatoprotective effect of silymarin. *World J Hepatol* 6: 144-149.
- Yamamoto Y, Yoshizawa T, Fukuda T, Shirode-Fukuda Y, Yu T, Sekine K, Sato T, Kawano H, Aihara K, Nakamichi Y, Watanabe T, Shindo M, Inoue K, Inoue E, Tsuji N, Hoshino M, Karsenty G, Metzger D, Chambon P, Kato S, Imai Y (2013) Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. *Endocrinology*. 154(3): 1008-1020.